A Case Series of Tirzepatide Treatment in Patients with Type 2 Diabetes, Chylomicronemia and Genetic Variants Affecting Lipoprotein Lipase
Main Article Content
Abstract
Background/Aim: Tirzepatide has been shown to improve glycemic control, improve insulin sensitivity, increase adipocyte lipoprotein lipase (LPL) activity and decrease apolipoprotein C3 levels. We previously reported that a patient who had type 2 diabetes (T2DM), persistent chylomicronemia and heterozygosity for LPL deficiency had resolution of his chronic chylomicronemia and near normalization of serum triglycerides in response to tirzepatide therapy. Therefore, the aim of this study was to perform a case series using tirzepatide treatment in a group of patients with T2DM or metabolic syndrome, chylomicronemia and multiple genetic variants affecting LPL to verify similar results in a larger group of patients with Metabolic Chylomicronemia Syndrome.
Method: 61 patients with chylomicronemia who were referred to our lipid clinic were screened. Fiftyeight out of 61 patients had identifiable genetic variations in one of the 7 genes associated with chylomicronemia and 57/61 had T2DM. Twenty of these chylomicronemic patients (19 with T2DM and 1 with prediabetes) were able to be treated with tirzepatide and 17/20 had a genetic variant associated with a decrease in LPL: 5 having heterozygosity for LPL deficiency, 10 having variants of apolipoprotein A5, 1 with a variant of the LMF-1 gene and one patient with prediabetes who was a compound heterozygote having LPL heterozygosity plus an apolipoprotein A5 variant. Three patients had no identifiable genetic variation associated with chylomicronemia and all were treated with tirzepatide given to maximum tolerated dose.
Results: In all patients, there was a resolution of their chylomicronemia. In patients who had a history of chylomicronemia induced pancreatitis or abdominal pain, there were no episodes of pancreatitis or abdominal pain while on tirzepatide. Pre-/post lipid profile averages as follows: total triglyceride decreased from 9.25 to 3.19 mmol/L (-65%, P value < 0.006), total cholesterol decreased from 5.12 to 3.72 mmol/L (-27%, P < 0.0013), LDL cholesterol decreased from 2.14 to 1.72 mmol/L (-20%, P<0.40), non-HDL cholesterol decreased from 4.09 to 2.97 mmol/L (-27%, P <0.002). HDL cholesterol increased from 0.74 to 0.84 mmol/L (+13%, P <0.023). In addition, the average A1c decreased from 7.6% to 6.0% (-15%, P <0.0001) and body weight decreased from 98.0 to 91.8 kg (-6.5%, P <0.0001).
Conclusion: In this case series of patients with a history of chylomicronemia, T2DM/ metabolic syndrome and multiple gene variants affecting LPL, tirzepatide caused a resolution of chylomicronemia with a significant decrease in total triglyceride, total cholesterol and non-HDL cholesterol levels as well as an increase of HDL cholesterol. Tirzepatide resulted in a significant improvement of A1C as well as a decrease in body weight. The mechanism(s) underlying these effects is(are) not completely understood but warrants further investigation. The results of this case series suggest that tirzepatide may be an agent useful for the treatment of patients with T2DM and chylomicronemia who have genetic variants affecting LPL.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2) Brunzell JD, Auwerx JH, Babirak SP, Fujimoto WY, and Hayden MR. Familial Lipoprotein Lipase Deficiency. In: Arteriosclerosis VIII, (Crepaldi G, Gotto AM, and Manzato E eds.), New York, Excerpta Medica; 165-167, 1989.
3) Chait A and Eckel RH. The chylomicronemia syndrome is most often multifactorial. Ann InterMed. 2019;170: 626-634.
4) Brunzell J, Deeb S. Familial lipoprotein lipase deficiency, apo CII deficiency, and hepatic lipase deficiency. In: Scriver C, Beaudet A, Sly W, Vale D, eds. The Metabolic and Molecular Basis of Inherited Disease. 8th ed. New York: McGraw-Hill; 2001:2789-816.
5) Hegele RA, Ginsberg HN, Chapman MJ et al. The polygenetic nature of hypertriglyceridemia: implications for the definition, diagnosis and management. Lancet Diab and Endo. 2014; 2(8): 655-666.
6) Surendran RP, Visser ME, Heemelaar S, Wang J, et al. Mutations in LPL, APOC2, APOA5, GPIHBP1 and LMF1 in patients with severe hypertriglyceridemia. J Intern Med. 2012; 272:185-96.
7) Fojo SS, Brewer HB. Hypertriglyceridemia due to genetic defects in lipoprotein lipase and apolipoprotein C-II. J Intern Med. 1992; 231:669-677.
8) Calandra S, Priore Oliva C, Tarugi P, Bertolini S. APOA5 and triglyceride metabolism, lesson from human APOA5 deficiency. Curr Opin Lipidol. 2006; 17:122-7.
9) Rios JJ, Shastry S, Jasso J, Hauser N, Garg A, Bensadoun A, et al. Deletion of GPIHBP1 causing severe chylomicronemia. J Inherit Metab Dis. 2012; 35:531-40.
10) Hegele RA, Berberich AJ, Ban MR, et al. Clinical and biochemical features of different molecular etiologies of familial chylomicronemia. J Clin Lipidol 2018; 12: 920–927.
11) Haller JF, Mintah IJ, Shihanian LM, Stevis P, Buckler D, AlexaBraun CA, et al. ANGPTL8 requires ANGPTL3 to inhibit lipoprotein lipase and plasma triglyceride clearance. J Lipid Res. 2017; 58:1166- 1173.
12) Chi X, Britt EC, Shows HW, Hjelmaas AJ, Shetty SK, Cushing EM, et al. ANGPTL8 promotes the ability of ANGPTL3 to bind and inhibit lipoprotein lipase. Mol Metab. 2017; 6:1137-1149.
13) Hegele RA, Ginsberg HN, Chapman MJ, Nordestgaard BG, Kuivenhoven JA, Averna M, et al; European Atherosclerosis Society Consensus Panel. The polygenic nature of hypertriglyceridemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol. 2014; 2:655-66.
14) Babirak SP. The detection and characterization of the heterozygote state for LPL deficiency. Arteriosclerosis 1989: 9(3): 316-334.
15) Babirak SP, Brown BG, and Brunzell JD. Premature coronary disease, elevated apolipoprotein B, and low lipoprotein lipase. Arteriosclerosis 8: 575a, 1988.
16) Chait A, Brunzell JD. Severe hypertriglyceridemia: role of familial and acquired disorders. Metabolism. 1983; 32:209-214.
17) Gaudet D, Brisson D, Tremblay K, et al. Targeting APOC3 in the familial chylomicronemia syndrome. N Engl J Med 2014; 371: 2200–06.
18) Witztum JL, Gaudet D, Freedman SD, Alexander VJ, Digenio A, Williams KR, Yang Q, Hughes SG, Geary RS, Arca M, Stroes ESG, Bereron J, Soran H, Civeira H, Hemphill L, Tsimikas S, Blom DJ,O’Dea and Bruckert E. Volanesorsen and triglyceride levels in Familial chylomicronemia syndrome. N Engl J Med 2019; 381:531-542.
19) Stroes ESG, Alexander VJ and Karwatowska-Prokopczuk E. Olezarsen, acute pancreatitis, and familial pancreatitis syndrome. N Engl J Med 2024; 390:1781-92.
20) Watts GF, Rosenson RS, Hegele RA, et al. Plozasiran for Managing persistent chylomicronemia and pancreatitis risk. N Engl J Med Sept 2 2024, doiEpub ahead of print, PMID; 39225259.
21) Babirak SP. Tirzepatide therapy in a patient with type 2 diabetes mellitus, chylomicronemia and heterozygosity for lipoprotein lipase deficiency. AACE Clinical Case Report 2023; 9;128-130.
22) Wilson JM, Nikooienejad A, Robins DA, Roell WC, et al. The dual glucose-dependent insulinotropic peptide and glucagon-likepeptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes. Diabetes Obes Metabolism.2020:22(12): 2451-2459.
23) Pirro V, Roth KD, Lin Y et al. effects of tirzepatide, a dual GIP and GLP–1 receptor agonist, on lipid and metabolite profiles in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2022; 7 (2): 363–378.
24) Kim SJ. Activation of lipoprotein lipase by glucose-dependant insulinotropic polypeptide in adipocytes. J Biol Chem. 2007; 282:8557-8567.
25) Kim SJ, Nian C, McIntosh CH.GIP increases human adipocyte LPL expression through CREB and TORC2-mediated trans-activation of the LPL gene. J Lipid Res. 2010; 51(11):3145-57.